Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

APLSNYSE / NASDAQHealthcareMid cap

$41.03$0.00 (0.0%)

Last close · Data as of May 15, 2026

Market cap
$5.3B
P/E
234.6x
EV / EBITDA
75.2x
Revenue
$1.0B
Net margin
2.2%
ROCE
7.4%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Apellis Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 15 May 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

This period includes a one-day price step on 31 Mar 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change $0.00 (0.0%) from $41.03 to $41.03 · Last close May 15, 2026

Best weekday to invest, historically

The same weekly amount in APLS, bought on each weekday since 2021.

News & filings

What Apellis Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity rose from -86.6% to 6.0% between fiscal 2024 and fiscal 2025.

Concerns (1)

  • The P/E of 234.6 is more than four times the peer median of 17.5.
  • Prices are as of 15 May 2026; price-based points are paused until newer prices arrive.
  • This period includes a one-day price step on 31 Mar 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 15 May 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Read moreShow less

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Shares outstanding
124.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$5.3B
P/E
234.6x
P/B
14.2x
EV / EBITDA
75.2x
EV / Sales
5.2x
P/S
5.2x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
5.5%
Net margin
2.2%
EBITDA margin
7.0%
ROE
6.0%
ROCE
7.4%
ROA
2.1%
Asset turnover
0.93

Growth

Revenue
$1.0B
Revenue growth, 1Y
28.5%
Revenue CAGR, 3Y
137.0%
Net profit growth, 1Y
-111.3%
Free cash flow
$45.0M

Solvency

Current ratio
3.14
Debt / Equity
1.28
Debt / Assets
0.44
CFO / Net profit
2.02
Cash / Market cap
8.9%

Where the revenue went

Of every $100 of FY2025 revenue, $2 was left as net income.

Apellis Pharmaceuticals, Inc. income statement flow, FY2025
Apellis Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$102.2M
RevenueGross profit$901.5M
Gross profitResearch and development$295.9M
Gross profitSelling, general and administrative$550.3M
Gross profitOperating income$55.4M
Operating incomePretax income$24.1M
Operating incomeInterest and other expense$31.3M
Pretax incomeTax and other$1.7M
Pretax incomeNet income$22.4M

Revenue and net profit

Revenue grew 28.5% in FY2025; net profit is the dashed line.

Apellis Pharmaceuticals, Inc. revenue and net profit by fiscal year
Apellis Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$75.4M-$652.2M
FY2023$396.6M-$528.6M
FY2024$781.4M-$197.9M
FY2025$1.0B$22.4M

Cash flows

FY2025: $45.3M from operations, $45.0M free after investment (dashed).

Apellis Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Apellis Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$513.7M-$515.3M
FY2023-$594.7M-$595.5M
FY2024-$87.9M-$88.3M
FY2025$45.3M$45.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.0B+28.5%1Y
EBITDA
$70.0M
Net profit
$22.4M
Cash from operations
$45.3M
Free cash flow
$45.0M
Revenue CAGR, 3Y
137.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.0B$70.0M$22.4M$45.0M6.0%+28.5%-111.3%

Monthly returns

Month-by-month returns of APLS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.1B
Liabilities$705.1M
Equity$370.1M
Paid-in capital$3.4B
Retained earnings-$3.0B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; APLS highlighted.

P/E against peers

APLS trades at 234.6x earnings against a peer median of 17.5x (a 1242% premium).

Not shown (no positive earnings and no EV / Sales): Teleflex Incorporated, RadNet, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Apellis Pharmaceuticals, Inc.APLSthis companyP/E ↑ premium$5.3B234.6x14.2x6.0%75.2x
TG Therapeutics, Inc.TGTX$6.2B13.9x9.6x69.0%47.5x
PTC Therapeutics, Inc.PTCT$5.9B8.6x—-332.5%7.5x
Teleflex IncorporatedTFX$5.8B-6.5x1.9x-29.0%27.1x
Ligand Pharmaceuticals IncorporatedLGND$4.7B38.0x4.6x12.2%25.3x
Indivior Pharmaceuticals, Inc.INDV$4.4B21.1x-44.7x-212.1%15.1x
Amneal Pharmaceuticals, Inc.AMRX$4.3B59.9x-60.9x-101.8%11.1x
RadNet, Inc.RDNT$4.2B-222.6x3.8x-1.7%16.7x
Veracyte, Inc.VCYT$4.0B60.1x3.0x5.1%40.9x
Peer median—17.5x3.0x-15.3%21.0x

Year-to-date ROI

APLS since 1 January, against earlier years.

Historical volatility

APLS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Apellis Pharmaceuticals, Inc. operating margin by fiscal year
Apellis Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY2022-788.4%
FY2023-130.4%
FY2024-21.1%
FY20255.5%
LineFY2025
Cost of revenueCost Of Revenue$102.2M
Gross profitGross Profit$901.5M
Operating expensesOperating Expense$846.1M
Research and developmentResearch And Development$295.9M
Total expensesTotal Expenses$948.4M
Pretax incomePretax Income$24.1M

Learn while you research

Academy chapters picked for Apellis Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 234.6, learn when high multiples are justified.6 min read
  3. 03 Growth Investing28% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →